Announcement
28 Sep 2022
In September 2022, U.S. BARDA provided funding to support the FDA clearance of a combined SARS-CoV-2 and influenza A and B test on a point-of-care system LIAISON NES instrument.
Source
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
Implementation date
28 Sep 2022
Revocation date:
No revocation date
On 28 September 2022, Biomedical Advanced Research and Development Authority (BARDA) announced providing USD 31 million in funding to DiaSorin Molecular LLC. The stated objective is to help the com...
See all
This state act is not part of any Thread yet.